Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients market is poised for significant growth, expanding biopharmaceutical pr ...

The Trump administration is directing the Department of Health and Human Services to identify about 26 “critical medicines.” ...

RUSAN PHARMA PRIVATE LIMITED announced that the USFDA has granted GMP approval for its API facility in Ankleshwar (Gujarat, India).

US pharma major AbbVie yesterday announced a $195 million investment in its North Chicago, Illinois manufacturing plant to ...

In Asia, firms such as Aurobindo Pharma, Sun Pharmaceutical Industries, and Zhejiang Hisun Pharmaceutical have established themselves as key players in the antibiotics active pharmaceutical ingredient ...

Ajinomoto Bio-Pharma Services is taking full control of an API manufacturing facility in India as the CDMO continues to bulk up in a market that favors companies that can do it all.

As pharma companies big and small play up their U.S. investment plans during the second Trump administration, the particulars ...

The global active pharmaceutical ingredients market size is projected to reach USD 359.45 billion by 2030, and it is expected to exhibit a CAGR of 5.85% from 2025 to 2030, according to a new ...

pharma& Receives EMA Approval for Pegasys® Manufacturing Site Variation, Adding Loba biotech for API Production and Securing a Stable, Long-term Supply • Loba biotech, a manufacturing site in Austria, ...

To learn more about LGM Pharma’s unique suite of API services and drug product CDMO services, request a meeting at [email protected] with company executives at 2023 DCAT Week, March 20-23, in ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

The global biopharma firm will build a new API production facility near its global headquarters in North Chicago.